Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Liu, Joyce F

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. [electronic resource] - The Lancet. Oncology Oct 2014 - 1207-14 p. digital

Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

1474-5488

10.1016/S1470-2045(14)70391-2 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Ovarian Epithelial
Cisplatin--administration & dosage
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Neoplasms, Glandular and Epithelial--drug therapy
Ovarian Neoplasms--drug therapy
Phthalazines--administration & dosage
Piperazines--administration & dosage
Quinazolines--administration & dosage
Risk Assessment
Survival Analysis
Treatment Outcome